Skip to content

Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor

Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07447908
Acronym
TRUE-HF 2
Enrollment
360
Registered
2026-03-04
Start date
2026-06-16
Completion date
2029-09-01
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apple Watch, Cardiopulmonary Exercise Test, Heart Failure, Heart Failure - NYHA II - IV, Heart Failure Patients

Keywords

Apple Watch, CPET, Heart Failure, Artificial Intelligence, Wearable Technology, Wearable, Remote monitoring

Brief summary

Heart Failure (HF) is a complex disease associated with the highest burden of cost to the healthcare system. The cardiopulmonary exercise test (CPET) is instrumental in determining the prognosis of patients with HF. This multicentre study will validate whether aggregate biometric data from the Apple Watch combined with demographic, cardiac, and biomarker testing can improve our ability to predict heart failure outcomes among a diverse outpatient HF population.

Detailed description

Traditionally, clinicians have relied on static snapshots of patients to determine clinical status and estimate prognosis. More advanced cardiac centres rely on CPET for objective prognosis. There is an unmet need for a more widely available, accessible, and longitudinal assessment of cardiopulmonary fitness and clinical status to better monitor and prognosticate patients. Wearable devices such as Apple Watch hold great promise in this regard, as they provide near-continuous monitoring of biometric data. In TRUE-HF, we used Apple Watch data to build a novel model for serial daily prediction of cardiopulmonary fitness that is strongly correlated with CPET pVO2. In TRUE-HF2, we seek to prospectively validate the relationship between wearable data and changes in cardiopulmonary fitness, and early warnings of worsening heart failure as measured through decompensation, clinical deterioration, unplanned healthcare utilization, hospitalization, need for advanced heart failure therapies, and mortality. The goal is to enable equitable access to cardiopulmonary fitness assessment for HF patients who may otherwise face significant barriers to tertiary-centre testing, including travel burden, geography, and limited local resources. Our study has 5 research questions based on 2 primary outcomes and 3 secondary outcomes in clinically diverse adult ambulatory heart failure patients : Primary Research Questions: 1. Can surrogates of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data predict significant reductions in cardiorespiratory fitness in heart failure patients? 2. Can surrogates of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data predict early warnings of worsening heart failure? Secondary Research Questions: 3. Can biometric data from Apple Watch in combination with clinical and/or demographical data be used to estimate cardiorespiratory fitness measurements and changes, as assessed by CPET? 4. Can biometric data from Apple Watch in combination with clinical and/or demographical data from the Apple Watch be used to improve risk prediction models of worsening heart failure as combined (primary) or stratified (secondary) outcomes? 5. Can biometric data from Apple Watch in combination with clinical and/or demographical data from the Apple Watch be used to predict markers of poor prognosis specifically as defined by the SHFM, BNP, Quality of life (QOL) indicators, and CPET parameters?

Interventions

None listed

Sponsors

University Health Network, Toronto
Lead SponsorOTHER
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* broad age range (\> 18 years of age) * NT-proBNP \> 400 or 1000 if in AF * Within 3 months post discharge from HF hospitalization/ HF ED visit/ HF rapid clinic visit with intensification of diuretic therapy * NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction * Literacy in English * Patient provided informed consent

Exclusion criteria

* Unable to perform a CPET based on the standard protocol * End stage renal disease requiring dialysis * Living with LVAD * MRP deems patient unfit for the study * Post heart transplant

Design outcomes

Primary

MeasureTime frameDescription
Prediction of Cardiopulmonary Exercise Test Parameters7 monthsMeasure the predictive power of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data against reductions in measured cardiorespiratory fitness, using K5 device in heart failure patients
Prediction of worsening heart failure7 monthsMeasure predictive power of cardiorespiratory fitness estimated from data obtained from Apple Watch in combination with clinical and/or demographical data against worsening heart failure from clinical visits, bloodwork, and medication changes.

Secondary

MeasureTime frameDescription
Prediction of Cardiopulmonary Exercise Test Parameters7 monthsMeasure predictive power of biometric data obtained from Apple Watch in combination with clinical and/or demographical data against cardiorespiratory fitness measurements as assessed by Cardiopulmonary Exercise Test using a K5 device.
Prediction of worsening Heart Failure as a combined and stratified outcome2 yearsMeasure predictive power of biometric data obtained from Apple Watch in combination with clinical and/or demographical data against worsening heart failure
Prediction of existing markers of poor prognosis2 yearsMeasure predictive power of biometric data obtained from Apple Watch in combination with clinical and/or demographical data from the Apple Watch be against existing markers of poor prognosis specifically as defined by the SHFM, BNP, Quality of life (QOL) indicators, and CPET parameters as measured by K5 device

Countries

Canada

Contacts

CONTACTRyan Li, MASc
ryan.li@uhn.ca6479669330
CONTACTBen Kim, PhD
ben.kim@uhn.ca
STUDY_CHAIRHeather Ross, MD

University Health Network, Toronto

PRINCIPAL_INVESTIGATORChris McIntosh, PhD

University Health Network, Toronto

PRINCIPAL_INVESTIGATORYasbanoo Moayedi, MD

University Health Network - Toronto General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026